Unique ID issued by UMIN | UMIN000039353 |
---|---|
Receipt number | R000044865 |
Scientific Title | Effect of once, twice, or thrice weekly administration of intravenous levocarnitine in the treatment of patients with carnitine deficiency undergoing hemodialysis: a retrospective observational study. |
Date of disclosure of the study information | 2020/02/01 |
Last modified on | 2020/03/09 18:08:48 |
Effect of once, twice, or thrice weekly administration of intravenous levocarnitine in the treatment of patients with carnitine deficiency undergoing hemodialysis: a retrospective observational study.
Effect of levocarnitine on hemodialysis
Effect of once, twice, or thrice weekly administration of intravenous levocarnitine in the treatment of patients with carnitine deficiency undergoing hemodialysis: a retrospective observational study.
Effect of levocarnitine on hemodialysis
Japan |
patients with carnitine deficiency undergoing hemodialysis
Nephrology |
Others
NO
We aimed to investigate the usefulness of intravenous (IV) levocarnitine administration in patients with carnitine deficiency undergoing hemodialysis (HD). We compared the effects of IV-levocarnitine administration at various doses in the treatment of HD patients with renal anemia, hypotension, cardiac insufficiency, and muscle weakness. Levocarnitine, in oral and injected formulations, has been reported to reduce the required dose of erythropoiesis-stimulating agents (ESA) in HD treatment. However, the optimal frequency of levocarnitine administration required for this effect remains unclear. We compared the effects of levocarnitine administration at several frequencies in the treatment of carnitine-deficiency patients with renal anemia undergoing HD, through the measurement of total carnitine (TC) and free carnitine (FC) serum levels.
Efficacy
Confirmatory
Pragmatic
Not applicable
renal anemia
total carnitine, free carnitine serum levels,hypotension, cardiac insufficiency, and muscle weakness. the required ESA
Observational
Not applicable |
Not applicable |
Male and Female
We compared the effects of levocarnitine administration at several frequencies in the treatment of carnitine-deficiency patients with renal anemia undergoing HD, through the measurement of total carnitine (TC) and free carnitine (FC) serum levels.
The study excluded patients who (1) had previously received oral or IV levocarnitine; (2) had received any carnitine supplement; (3) had difficulty communicating due to dementia or other factors; (4) had acute inflammation; (5) had received immunosuppressants, steroids, or antibiotics; and (6) had received blood transfusion in the past 6 months.
100
1st name | Shohei |
Middle name | |
Last name | Sawada |
Ijinkai General Takeda Hospital,
Division of Nephrology & Hemodialysis, Hemodialysis Center,
6191495
28-1, Ishidamoriminami-machi, Hushimi-ku, Kyoto City, Kyoto Prefecture; 601-1495, Japan
075-572-6331
shoheisawada@yahoo.co.jp
1st name | Shohei |
Middle name | |
Last name | Sawada |
Ijinkai General Takeda Hospital,
Division of Nephrology & Hemodialysis, Hemodialysis Center,
6191495
28-1, Ishidamoriminami-machi, Hushimi-ku, Kyoto City, Kyoto Prefecture; 601-1495, Japan
075-572-6331
shoheisawada@yahoo.co.jp
Division of Nephrology & Hemodialysis, Hemodialysis Center, Ijinkai General Takeda Hospital,
Division of Nephrology & Hemodialysis, Hemodialysis Center, Ijinkai General Takeda Hospital,
Other
Ijinkai General Takeda Hospital,
28-1, Ishidamoriminami-machi, Hushimi-ku, Kyoto City, Kyoto Prefecture; 601-1495, Japan
075-572-6331
shoheisawada@yahoo.co.jp
NO
医仁会武田総合病院(京都府)
2020 | Year | 02 | Month | 01 | Day |
Unpublished
101
Total 101 patients. TC and FC before levocarnitine(LC) were 33 and 21 microM/L. 85 had carnitine deficiency. After thrice weekly LC, TC and FC increased to 372 and 228. Treatment also led to a 40% reduction in ESA and decreased intradialytic muscle cramp score. After twice weekly LC, TC and FC increased to 314 and 202, whereas, after once weekly LC, TC and FC increased to 150 and 97. The effect of once-, twice-, or thrice weekly LC on the required ESA dosage continued for 24 weeks.
2020 | Year | 02 | Month | 01 | Day |
Completed
2020 | Year | 01 | Month | 31 | Day |
2020 | Year | 03 | Month | 03 | Day |
2020 | Year | 03 | Month | 03 | Day |
2021 | Year | 03 | Month | 09 | Day |
2021 | Year | 03 | Month | 09 | Day |
2021 | Year | 03 | Month | 09 | Day |
2021 | Year | 03 | Month | 10 | Day |
retrospective observational study
2020 | Year | 02 | Month | 01 | Day |
2020 | Year | 03 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044865
Research Plan | |
---|---|
Registered date | File name |
2020/03/09 | エルカルチン実施計画書_Ver1.0_FIX.pdf |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |